NASDAQ: GNPXGenprex Inc Stock
$2.48-0.13 (-4.98%)
Updated May 7, 2024
GNPX Price
$2.48
Fair Value Price
$4.93
Market Cap
$4.74M
52 Week Low
$2.09
52 Week High
$42.40
P/E
-0.11x
P/B
0.64x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$30.86M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.44
Operating Cash Flow
-$25M
Beta
1.51
Next Earnings
May 22, 2024
Ex-Dividend
N/A
Next Dividend
N/A
GNPX Overview
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GNPX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GNPX ($2.48) is undervalued by 49.66% relative to our estimate of its Fair Value price of $4.93 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
GNPX ($2.48) is significantly undervalued by 49.66% relative to our estimate of its Fair Value price of $4.93 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
GNPX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GNPX due diligence checks available for Premium users.
Be the first to know about important GNPX news, forecast changes, insider trades & much more!
GNPX News
Valuation
GNPX fair value
Fair Value of GNPX stock based on Discounted Cash Flow (DCF)
Price
$2.48
Fair Value
$4.93
Undervalued by
49.66%
GNPX ($2.48) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GNPX ($2.48) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GNPX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GNPX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.11x
Industry
4.02x
Market
32.4x
GNPX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.64x
Industry
6.06x
GNPX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GNPX's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.9M
Profit Margin
0%
GNPX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$10.7M
Liabilities
$3.3M
Debt to equity
0.44
GNPX's short-term assets ($7.53M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GNPX's short-term assets ($7.53M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GNPX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
GNPX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.0M
Investing
-$9.8k
Financing
$10.0
GNPX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GNPX vs Biotech Stocks
Genprex Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.